Dr. Adam J. Fein, president of Drug Channels Institute (DCI) and the author of Drug Channels, invites you to join him for DCI’s latest live video webinar:
Drug Channel Implications of the Inflation Reduction Act
This event will be broadcast live on
Friday, April 5, 2024, from 12:00 p.m. to 1:30 p.m. ET
This post describes the event and explains how to purchase a registration. The webinar will be broadcast from the Drug Channels studio in beautiful downtown Philadelphia.
This event is part of The Drug Channels 2024 Video Webinar Series.
WHAT YOU WILL LEARN
In 2023, the Inflation Reduction Act of 2022 (IRA) began to alter the Medicare Part D program and trigger changes in beneficiary out-of-pocket spending, drug prices, pharmacy economics, and market access strategies. The IRA’s impact will extend far beyond the Medicare program into many aspects of the overall drug channel.
In this all-new webinar, Dr. Fein will unpack the intended and unintended consequences of the IRA for the commercial market and drug channel participants, including:
- What’s ahead for brand-name drug list and net prices
- The coming battles over high-list/high-rebate products
- The Medicare Advantage boom and the collapse of the stand-alone PDP market
- The gross-to-net bubble outlook for Part D
- The IRA’s spillover impact on the gross-to-net bubble in commercial markets
- How the IRA will impact Medicaid rebates and change the 340B Drug Pricing Program
- What’s ahead for utilization management
- Retail pharmacies’ coming financial challenges
- The uptick in consolidation of physician practices
- Biosimilar market uncertainties
- And much more!
PLUS: During the webinar, Dr. Fein will give participants an opportunity to unmute themselves and ask live questions. The webinar will last 90 minutes to accommodate audience questions.
As always, Dr. Fein will clearly distinguish his opinions and interpretations from the objective facts and data. He will also draw from exclusive information found in DCI’s new 2024 Economic Report on U.S. Pharmacies and Pharmacy Benefit Managers.
Please note that Dr. Fein will focus on the IRA’s patient and commercial market impacts. The potential effect of the IRA on manufacturers’ new drug research and development strategies is beyond the scope of this webinar.
Read on for full details on pricing and registration.
Read more »
